HAV VP4-VP2, Hepatitis A Virus Antigen, Recombinant
| Full Name |
HAV VP4-VP2, Hepatitis A Virus Antigen, Recombinant
|
Abbreviated Name-1 |
Hepatitis VP4-VP2; |
| Documents |
|---|
| Figures |
|---|
| Reference |
|---|
Kusov Y, et al. Silencing of hepatitis A virus infection by small interfering RNAs. J. Virol. Jun 2006; 80(11): 5599-5610.
Nainan OV, et al. iagnosis of hepatitis a virus infection: a molecular approach. Clin. Microbiol. Rev. Jan 2006; 19(1): 63-79.
Fensterl V, et al. Hepatitis A virus suppresses RIG-I-mediated IRF-3 activation to block induction of beta interferon. J. Virol. Sep 2005; 79(17): 10968-10977.
|
|
Description |
Hepatitis A Virus (HAV) VP4-VP2 is an E. coli-derived recombinant. The protein contains the VP4-VP2 immunodominant region. HAV, the prototype of the genus Hepatovirus, belongs to the family Picornaviridae. Its 7.5-kb single-stranded RNA genome bears different distinct regions: the 5' and 3' noncoding regions (NCR), the P1 region, which encodes the structural proteins VP1, VP2, VP3, and a putative VP4, and the P2 and P3 regions encoding nonstructural proteins associated with replication. Hepatitis A Virus (HAV) VP4-VP2 encodes a single polyprotein which is posttranslationally processed into the functional structural and nonstructural proteins. |
Source |
E. coli |
Purity |
Protein is >90% pure as determined by 10% PAGE (coomassie staining). |
Storage |
Protein is shipped at ambient temperature. Upon arrival, store at -20°C. |
Concentration |
1 mg/ml in 10 mM CBB, pH 9.6, 0.1% SDS, 50% glycerol |
Stability |
Five years frozen. one month in solution at room temperature. |
Specificity |
Immunoreactive with sera of HAV-infected individuals |
Applications |
Antigen in ELISA and Western blots, excellent antigen for detection of HAV with minimal specificity problems |
Note |
; |
Related Products
 |
1 |
Custom Recombinant Protein Services: Guaranteed E. coli Expression Package-3 mg purified soluble protein from $2,200 . |
2 |
Bacterial Expression System: GenScript has developed BacPowerTM technologies to tackle hard-to-express and hard-to-dissolve proteins. |
3 |
Yeast Expression System: GenScript's proprietary YeastHIGHTM technology combines the advantages of the bacterial and eukaryotic expression systems. |
4 |
Baculovirus/Insect Cell Expression System: GenScript developed BacuVanceTM platform for the secretion of recombinant proteins from baculovirus-infected insect cells. |
5 |
Mammalian Cell Expression System: The proprietary 293 and CHO suspension system platform promotes fast production and delivery of recombinant proteins and monoclonal antibodies up to grams level. |
|
